7/22/2008

Genentech's executives have not commented on Roche Holding's $43.7 billion takeover bid, but some employees are concerned that the offer was too sudden and could unsettle the companies' partnership. Analysts expect Roche to make a higher bid, one that reflects the potential of the U.S. biotech firm's pipeline. Roche's move could encourage other major drugmakers to consider acquiring profitable biotech pioneers, industry experts said.

Related Summaries